No abstract available.
Methylprednisolone*

Systemic corticosteroid arrests the progression of vitiligo and leads to repigmentation, but it may produce side effects. It has been reported that the maximum effect for corticosteroid can be achieved without major side effects when it is used at high doses over a short period of time. Recently, narrowband UVB has been used to treat vitiligo. However, there have been no reports on the effectiveness for a combined treatment with narrowband UVB and systemic corticosteroid. We encountered 2 cases of vitiligo patients who had rapid and effective repigmentation after combination therapy with high dose methylprednisolone and narrowband UVB. Intravenous high dose (25 mg/kg) of methylprednisolone for 3 days was followed by narrowband UVB once or twice weekly. After 2 months, rapid improvements were seen in both patients with >75% repigmentation. Combination treatment with high dose methylprednisolone therapy and narrowband UVB may be an effective therapeutic option for vitiligo.
Humans ; Methylprednisolone ; Vitiligo

No abstract available.
Methylprednisolone* ; Purpura, Thrombocytopenic, Idiopathic*

No abstract available.
Bone Cysts* ; Methylprednisolone*

Unicameral bone cysts have been treated by variable surgical methods, but reported with high recurrent rates. Recently, the treatment of unicameral bone cyst by topical injection of methylprednisolone acetate has been reported with excellent results. The authors treated 4 cases of the unicameral bone cyst by topical injection of methylprednisolone acetate and followed up for 3 years and 5 months to 4 years. The results were as follows: l. 3 cases were healed completely with obliteration of cyst cavity and 1 case was in residual healing process. 2. If the cavity persists or recurrs, it seems possible to cure the cyst by repeated local injection.
Bone Cysts ; Methylprednisolone

BACKGROUND: The risk of steroid-induced hyperglycemia is debated, and methylprednisolone is still used during spinal surgery. We have compared the blood glucose level in patients with metabolic syndrome treated with or without methylprednisolone. METHODS: This study was conducted in 68 adult patients who underwent elective spine surgery. Patients were classified into the following groups: methylprednisolone group (n = 39, group M), placebo group (n = 29, group P), group M patients with metabolic syndrome (n = 17, group MM), and group P patients without metabolic syndrome (n = 21, group NMP). Before and after injection of either 125 mg methylprednisolone or a placebo, we consecutively checked the blood glucose level every 30 minutes up to 4 hours. RESULTS: The blood glucose level was significantly increased in group M patients as compared to group P patients. The blood glucose level was more significantly increased in group MM as compared to group NMP patients. The increased blood glucose levels over 4 hours were 50 mg/dl in group MM and 35 mg/dl in group NMP patients. CONCLUSIONS: We recommend that close monitoring of the blood glucose level up to several hours after injection of a steroid should be seriously considered during spine surgery, particularly in patients with metabolic syndrome.
Adult ; Blood Glucose ; Humans ; Hyperglycemia ; Methylprednisolone ; Spine

Arachnoid cyst of the velum interpositum is unusual and causes symptoms similar to those seen with a third ventricular mass. This report describes a case in which the arachnoid cyst occupied the cistern of the velum interpositum and was coincident with multiple cranial neuropathies. The patient was treated by endoscopic fenestration of the cyst. The surgery resulted in decreased in the size of the cyst but aggravation of cranial neuropathies. The patient underwent methylprednisolone pulse therapy and intravenous immunoglobulin administration under the impression of the multiple cranial neuropathies and recovered completely 3 months later. The authors conclude that combined neurological disease that needs medical treatment should be differentiated and priority of the treatment should be determined carefully if arachnoid cyst is associated with unrelated or ambiguous neurological symptoms and signs. Careful considerations of cause and effect may avoid an unnecessary surgical manipulation
Arachnoid* ; Cranial Nerve Diseases* ; Humans ; Immunoglobulins ; Methylprednisolone

Tow patients with severe glomerulonephitis and their serum creatinine clearance of 6.0ml/min/1.73m2 in case 2 were treated with high dosage intravenous methylprednisolone, 30mg/kg given over one hour period on each of six slternate days. Follwing the ?ulse therapy, both patients with rapidly deteriorathin renal funtion began to inprove and theit serum creatinine clearance levels showed over douvble by sixdays In both patients treated early in the curse of their disease, creatinine clearance increased to 80ml/min/1.73m2 in case 2 after one year follow-up and in recent study, clinical and laboratory findings are within normal limit.
Creatinine ; Follow-Up Studies ; Humans ; Methylprednisolone*

Cystic lesions of the kidney were experimentally induced by a single injection of methylprednisolone acetate(MPA), 20mg/kg, and morphometric analysis and ultrastructural observations by means of trans. mission and scanning electron microscopes were carried out after 1,2,3 and 4 weeks to clarify the nature of the cysts and their Histogenesis. l. The cystic lesions developed by administration of MPA were categorized into tubular and glomerular cysts ; the former underwent gradual regression of its number after the first week together with reduction of its ratio to the renal volume, whereas the latter progressed. 2. The subcapsular cystic structures(average diameter of ll0um) was originated from the dilated collecting tubules by 180 degree rotation in regard with abnormality in maturation process of nephorgenic activity. 3. Abnormalities of both proximal and distal convoluted tubules were reflected by increases of tubular diameter(l.54~3.55 times) and nuclear density(1.77~l.72 times), representing a compensatory dilatation of tubular lumen in association with shortening of tubular length. 4.Convolution of tubules was reduced and parallel to the shortening of tubular length. The above morphometric and ultrastructural features support that cystic lesion in the subcapsular portion induced by administration of MPA arises from the subcapsular collecting tubules by maturation arrest of nephorgenic activity.
Dilatation ; Humans ; Kidney* ; Methylprednisolone ; Missions and Missionaries

Studies in animals indicate that aconitine or aconite has toxic effects in the visual system of a rabbit model. Such a toxic effects causes myelo-optic neuropathy in the visually evoked cortical potential(VECP) and histopathologic studies. Whether the administration of intravenous high-dose of methyprednisolone(MP) in the myelo-optic neuropathy caused by aconitine(1.5ml/kg, equivalent to 0.7mg/kg of aconitine) is experimentally effective remains uncertain. The group treated with MP(daily 30mg/kg X 2 for 3 days followed by 15mg/kg for 3 days) in addition to aconite was compared with the aconite alone group and the normal control group. In the MP treated group, increased recovery of onset latency, peak latency, and amplitude in VECP in comparision with the aconite alone group was recorded at 2 weeks (p<0.05). The MP treated group in comparision with the normal control group showed a significant delay in onset latency at 1 month and 2 months(p<0.05). But, the amplitude in both the MP treated group and the aconite alone group increased at 2 months and did not show a significant difference in comparision with the normal group(p<0.05). In histopathologic study, pathologic findings of myelin sheath in the MP treated group were less severe than in the aconite alone group generally. The true benefit of high-dose MP was at least clear within 2 weeks. The authors conclude that treatment with intravenous high-dose MP immediate after aconite injection may have some beneficial effects in recovery of neurologic function although such a treatment do not have the definite recovery in aconite induced myelo-optic neuropathy.
Aconitine ; Aconitum* ; Animals ; Methylprednisolone* ; Myelin Sheath